Physician calls for "radical new approach" to MS after positive Alemtuzumab Phase II 5-Year review
This article was originally published in Scrip
A lead investigator in the Phase 2 CAMMS223 trial of Genzyme's alemtuzumab (CamPath-H1) has called for " a radical new approach" to treatment of multiple sclerosis on the basis of 5-year follow up data presented on 14 October at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) International Conference in Goteborg, Sweden. Dr Alasdair Coles from the Department of Clinical Neurosciences, University of Cambridge hopes that MS physicians will look at the data from the study and move quickly to aggressive treatments such as alemtuzumab before overt and severe disability emerges, rather than adopting the "wait-and-see" approach with MS patients.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.